Holen Sie sich die Stockscreener-App
5.69
11.13%
0.57
Vorhandelsmarkt:
5.71
0.02
+0.35%
Schlusskurs vom Vortag:
$5.12
Offen:
$5.32
24-Stunden-Volumen:
1.26M
Relative Volume:
1.64
Marktkapitalisierung:
$304.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.05M
KGV:
-2.0177
EPS:
-2.82
Netto-Cashflow:
$-35.26M
1W Leistung:
+6.75%
1M Leistung:
+1.97%
6M Leistung:
+103.21%
1J Leistung:
-4.85%
1-Tages-Spanne:
$5.25
$5.87
1-Wochen-Bereich:
$5.03
$5.87
52-Wochen-Spanne:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Vergleichen Sie TARA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.69 | 274.37M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com India
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Trial tests first IV choline therapy for patients on long-term IV nutrition - Stock Titan
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - ulpravda.ru
Protara, Ceribell rise on FDA breakthrough designations - MSN
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times
Protara Therapeutics Receives Both FDA Breakthrough Therapy - GlobeNewswire
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN
Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn
Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm
Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Resistance Check: Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growth2025 Technical Patterns & Fast Entry Momentum Trade Alerts - moha.gov.vn
Can Protara Therapeutics Inc. stock attract ESG capital inflowsPrice Action & Daily Chart Pattern Signal Reports - DonanımHaber
Protara Therapeutics raises $86.3 million in offering - MSN
Protara Therapeutics Raises $86.3 Million in Offering - TipRanks
Protara Therapeutics, Inc. (NASDAQ: TARA) details $86.3M equity raise from stock sale - Stock Titan
What analysts say about Protara Therapeutics Inc stockSwing Trading Ideas & Get Alerts Before Market Turns Ugly - earlytimes.in
Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics, Inc. $TARA is Velan Capital Investment Management LP's 4th Largest Position - MarketBeat
Protara Therapeutics completes $75 million stock offering - MSN
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara announces proposed public offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
Protara therapeutics raises $75 million in public offering - Investing.com
Protara Therapeutics Closes $75 Million Public Offering - marketscreener.com
Protara therapeutics raises $75 million in public offering By Investing.com - Investing.com India
Protara Therapeutics (Nasdaq: TARA) closes $75M stock sale of 13.0M shares at $5.75 - Stock Titan
HC Wainwright & Co. reiterates Protara Therapeutics (TARA) buy recommendation - MSN
Is Protara Therapeutics Inc a good long term investmentOptions Trading Strategies & High Return Trading Strategies - earlytimes.in
Protara Therapeutics Inc. (TARA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025 - ts2.tech
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView — Track All Markets
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):